Scott Lassman, JD, partner in Goodwin's Technology and Life Sciences Group, explains why Citizen Petitions to the FDA are so controversial among generic and biosimilar stakeholders.
Transcript:
Why are Citizen Petitions to the FDA so controversial?
I think they’re controversial because people don’t understand exactly what they do and what they’re used for. Petitions, as the name implies, can be filed by anybody. They can be filed by citizens, they’re often filed by public interest organizations, but pharmaceutical companies also submit them and I think the concern is that they will submit them primarily to delay generic competition.
That might have been true in the past, but the law was changed back in 2007 to prevent that. The law currently says that the FDA review of a petition goes along one level and the review of the application, or the abbreviated new drug application (ANDA), goes along another. A petition cannot delay an approval of a generic application unless there’s a public health issue. The FDA actually puts out data every year about how many petitions are filed, how many will delay applications, and if you look at FDA’s own data, less than 1% of generic applications are delayed because of a petition.
The problem is really more of perception, and I think the issue is that there’s a lot of bad information out there. There have been a number of press reports, and actually academic publications, which purport to analyze petitions and have come up with the claim that they actually do delay generic competition. But, all of these publications, when they do their analyses, they rely on a lot of assumptions and they actually ignore FDA’s own data. I personally file a lot of petitions myself, so maybe I’m a little bit biased, but I’ve never had a petition that delayed a generic application. They raise issues, a lot of times the companies that submit them have the most information about the product, so they raise these issues with FDA, FDA considers them, but I think in very, very few cases, and only when public health is potentially involved, will it actually delay FDA’s decision on an application.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
BioRationality: No More Biosimilars—Just Biogenerics
February 3rd 2025Sarfaraz K. Niazi, PhD, argues that regulatory agencies should eliminate redundant clinical efficacy testing for biosimilars, recognizing them as "biogenerics" since physicochemical and in vitro biological comparisons are sufficient to ensure safety and efficacy.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
FTC Releases Second Report on PBMs Meddling in Generic Drug Markets
January 19th 2025The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with some drugs seeing thousands of percent markups, according to the Federal Trade Commission (FTC)’s second interim report on PBM practices.
Improving Biosimilar Access Through Global Regulatory Convergence
January 15th 2025Achieving global regulatory harmonization for biosimilar vaccines and immunotherapies is essential to improving market access, reducing costs, and enhancing patient outcomes by streamlining approval processes, fostering international collaboration, and addressing regulatory disparities.